disorders, systemic anaphylaxis or hypersensitivity responses, drug allergies, bone and joint related diseases and disorders, skin and eye related diseases and disorders, gastrointestinal tract and abdominal related diseases and disorders, hematological disorders, metabolic disorders, cerebellar dysfunction, disturbances of brain metabolism, transplant rejection related conditions, genitourinary related conditions, CNS related diseases and disorders like parkinson's disease, inflammatory or immunological diseases or disorders, cardiovascular diseases and disorders, oncological diseases and disorders.

18. A method of treatment of a disease mediated by kinase-activity comprising the administration, to a patient in need thereof, of a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a pharmaceutical composition according to claim 15.

19. The method according to claim 18, wherein the kinase is selected from SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or Myosin light chain kinase (MYLK or MLCK) or mutants thereof.

20. The method according to claim 19, wherein said treatment is systemic.

21. The method according to claim 19, wherein said administration is topical.

22. The method according to claim 19, wherein said disease is selected from the group consisting of an inflammatory

disease, an autoimmune disease, an allergic disorder, and an ocular disorder.


23. The method according to claim 18 or 19, wherein the disease is selected from the group consisting of pruritus, eczema, asthma, rhinitis, dry eye, ocular inflammation, allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, giant papillary conjunctivitis, fungal keratitis and uveitis.

24. The method according to claim 21, wherein said topical administration is to the skin.

25. The method according to claim 21, wherein said topical administration is to the eye.

26. The method according to claim 21, wherein said topical administration is intranasal or by inhalation.

27. A compound of formula (II), (IIIa) or (IIIb) wherein R^2 and R^3 are defined as in anyone of the preceding claims 1 to 13 and PG is a protecting group:



(II)

disorders, systemic anaphylaxis or hypersensitivity responses, drug allergies, bone and joint related diseases and disorders, skin and eye related diseases and disorders, gastrointestinal tract and abdominal related diseases and disorders, hematological disorders, metabolic disorders, cerebellar dysfunction, disturbances of brain metabolism, transplant rejection related conditions, genitourinary related conditions, CNS related diseases and disorders like parkinson's disease, inflammatory or immunological diseases or disorders, cardiovascular diseases and disorders, oncological diseases and disorders.

18. A compound according to any one of claims 1 to 14 or a pharmaceutical composition according to claim 15 for use in the treatment of a disease mediated by kinase-activity.

19. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 18, wherein the kinase is selected from SYK (Spleen Tyrosine Kinase) , LRRK2 (Leucine-rich repeat kinase 2) and/or Myosin light chain kinase (MYLK or MLCK) or mutants thereof.

20. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 19, wherein the treatment is systemic.

21. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 19, wherein the compound or the pharmaceutical composition is to be applied topically.

22. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 19, wherein the disease is selected from the group consisting of an inflammatory disease, an autoimmune disease, an allergic disorder, and an ocular disorder.


23. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 18 or claim 19, wherein the disease is selected from the group consisting of pruritus, eczema, asthma, rhinitis, dry eye, ocular inflammation, allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, giant papillary conjunctivitis, fungal keratitis and uveitis.

24. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 21, wherein the topical administration is to the skin.

25. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 21, wherein the topical administration is to the eye.

26. The compound or the pharmaceutical composition for use in the treatment of a disease mediated by kinase activity as claimed in claim 21, wherein the topical administration is to be intranasal or by inhalation.

27. A compound of formula (II), (IIIa) or (IIIb) wherein R^2 and R^3 are defined as in anyone of the preceding claims 1 to 13 and PG is a protecting group:



(II)